Aug. 19 at 9:32 AM
$ARDX I don’t view Raab as a failed CEO. He developed tenapanor, secured two FDA approvals, and turned Ardelyx into a commercial-stage company. His biotech builder record is strong.
But can he run a scaled commercial company as successfully as he built one?
TDAPA/CMS ended badly. The
$750M XPHOZAH target was withdrawn. Despite record IBSRELA demand, payer friction forced guidance from
$410–430M to
$350–370M. Then the CCO departed.
Raab’s greatest strength—high conviction—may be becoming overconfidence and poor risk calibration.
Q3 is critical. If payer issues improve and prescriptions convert into revenue, credibility can recover. Another execution/guidance failure would suggest a CEO-level management pattern, not isolated setbacks.
Raab now needs to justify his position through execution.
